[
  {
    "ts": null,
    "headline": "Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=ed52962159ecd3d3b7fbd109a805be9efffabde82da94ac5a98529acaa19dc6b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764597603,
      "headline": "Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 137659970,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HOLX",
      "source": "Yahoo",
      "summary": "Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=ed52962159ecd3d3b7fbd109a805be9efffabde82da94ac5a98529acaa19dc6b"
    }
  },
  {
    "ts": null,
    "headline": "VNRX: 3Q 2025 results reported; Revenues & EPS above our expectations; cost cutting very evident. At least seven major operational milestones have been achieved thus far in 2025.",
    "summary": "By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE SUMMARY VolitionRx’s (NYSE:VNRX): Management’s primary operational goal for 2025 is to secure multiple licensing agreements for human diagnostic applications. In September 2025, Volition began significant progress toward the goal by signing two licensing agreements : a Nu.Q NETs Research License with Werfen S.A. for",
    "url": "https://finnhub.io/api/news?id=e9f8543281b04e81de2243bc3c98b5a21f6b4c01f79da2ca3f0705a16523c778",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764588600,
      "headline": "VNRX: 3Q 2025 results reported; Revenues & EPS above our expectations; cost cutting very evident. At least seven major operational milestones have been achieved thus far in 2025.",
      "id": 137659971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HOLX",
      "source": "Yahoo",
      "summary": "By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE SUMMARY VolitionRx’s (NYSE:VNRX): Management’s primary operational goal for 2025 is to secure multiple licensing agreements for human diagnostic applications. In September 2025, Volition began significant progress toward the goal by signing two licensing agreements : a Nu.Q NETs Research License with Werfen S.A. for",
      "url": "https://finnhub.io/api/news?id=e9f8543281b04e81de2243bc3c98b5a21f6b4c01f79da2ca3f0705a16523c778"
    }
  }
]